Business Context and Reporting Period
Company: Alterity Therapeutics Limited
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: September 2020
Date Filed: September 18, 2020
Principal Executive Office: Level 3, 460 Bourke Street, Melbourne, VIC 3000, Australia
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a notice of a corporate action rather than a financial statement.
Material Changes
The primary material event disclosed in this filing is the issuance of Employee Stock Option Plan (ESOP) options, as detailed in Appendix 3G. No financial performance changes versus prior periods are reported in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document serves solely to notify the SEC of the ESOP option issuance and incorporates this information by reference into Registration Statements on Form S-8 and Form F-3.
Key Facts for Investor Verification
- Verify the specific number of ESOP options issued and the terms associated with them in Appendix 3G (not included in the provided text).
- Confirm the impact of this issuance on the company's total outstanding share count and potential dilution.
- Review the referenced Registration Statements (File Nos. 333-228671, 333-220886, and 333-231417) for broader context on capital structure.